Clinical trial
A Multicenter, Prospective, Cohort Study Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
NCT06878625 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Prospective, Cohort Study Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 6, 2024
- Completion date
- June 30, 2027
- Enrollment
- 138 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
evaluating the efficacy of trop-2 adc combination therapy in advanced triple-negative breast cancer